\
&
Contact us
\
&
Contact us
This was 11 months ago
LocationHybrid - Brussels and online
The European Commission, with support of European projects, is organising a workshop to explore gaps in standardisation across different domains and engage relevant industry stakeholders in the fields of Internet of Things (IoT), edge computing and swarm intelligence.
This workshop will examine the EU's role in international standardisation efforts and foster collaboration between ongoing IoT and edge computing projects. Participants will also engage in roadmap development, aimed at creating a common approach to standardisation in emerging technologies. Key standardisation committees and initiatives, such as ISO/IEC JTC 1/SC 41 (SC41) and SAREF (the Smart Applications REFerence ontology), will lead discussions focused on streamlining standardisation efforts across projects.
For more detailed information on the event, the agenda and the possibility to register, please visit the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
